logo
logo

Hopstem Completed 40 Million Usd Series B Financing, To Develop Safe, Effective And Affordable Ipsc Cell Therapies For Global Patients

Nov 01, 2021•almost 4 years ago

Round Type

series b

Health Care

Description

After A++ financing in May this year, HOPSTEM announced that the company has completed a round of near 40 million USD Series B financing, led by a top VC/PE in biomedical field, followed by Lilly Asia Ventures and current shareholder YuanBio Venture Capital.

Company Information

Company

Hopstem

About

CAYMAN ISLANDS, British Overseas Territory, Oct. 31, 2021 /PRNewswire/ -- After A++ financing in May this year, HOPSTEM announced that the company has completed a round of near 40 million USD Series B financing, led by a top VC/PE in biomedical field, followed by Lilly Asia Ventures and current shareholder YuanBio Venture Capital. HOPSTEM is an innovative startup company aiming to develop safe, effective and affordable iPSC cell therapy products for global patients.